The Role of Cavoportal and Renoportal Hemitransposition in Liver Transplantation

Betty Maillot; Guillaume Bouzille; Jean-Yves Mabrut; Edouard Girard; Alexis Laurent; Francis Navarro; Alexandre Chebaro; Laurence Chiche; Francois Faitot; Laurent Sulpice; Eric Vibert; Karim Boudjema

doi:10.12659/AOT.935892

08 March 2022 : Original article

The Role of Cavoportal and Renoportal Hemitransposition in Liver Transplantation

Betty Maillot^1ABCDEF*, Guillaume Bouzille^2C, Jean-Yves Mabrut^3B, Edouard Girard

^4B, Alexis Laurent^5B, Francis Navarro^6B, Alexandre Chebaro

^7B, Laurence Chiche^8B, Francois Faitot

^9B, Laurent Sulpice^1AB, Eric Vibert^10B, Karim Boudjema^1ACDEF

DOI: 10.12659/AOT.935892

Ann Transplant 2022; 27:e935892

Authors information Article notes Copyright and License information

¹Department of Hepatobiliary and Digestive Surgery, CHU Rennes, Pontchaillou Hospital, University of Rennes 1, Rennes, France
²Department of Medical Information and Medical Records, CHU Rennes, Pontchaillou Hospital, University of Rennes, INSERM, LTSI-UMR 1099, Rennes, France
³Department of General Surgery and Liver Transplantation, Hôpital de la Croix-Rousse, University of Claude Bernard Lyon 1, Hospices Civils de Lyon. National Institute for Health and Medical Research (INSERM) Unit 1052/CNRS-5286, Lyon, France
⁴Department of Digestive Surgery and Emergency, CHU Grenoble Alpes, La Tronche Hospital, University of Grenoble Alpes, Grenoble, France
⁵Department of Digestive and Hepatobiliopancreatic Surgery, AP-HP, Henri Mondor Hospital, University of Paris-Est Créteil, Inserm, UMR-955, Paris, France
⁶Department of Hepatobiliary Digestive Surgery and Hepatic and Pancreatic Transplantation, CHU Montpellier, Saint Eloi Hospital, University of Medicine Montpellier-Nîmes, Montpellier, France
⁷Department of Digestive Surgery and Transplantation, CHU Lille, Huriez Hospital, University of Medicine Henri Warembourg, Lille, France
⁸Department of Hepatobiliary and Hepatic Transplantation, CHU Bordeaux, Haut-Lévêque Hospital, University of Bordeaux, Bordeaux, France
⁹Department of General, Hepatic, Endocrine and Transplantation Surgery, CHU Strasbourg, Hautepierre Hospital, University of Strasbourg, Strasbourg, France
¹⁰Hepato-Biliary Center, AP-HP, Paul Brousse Hospital, University of Paris-Saclay, Paris, France

^*Corresponding Author: Betty Maillot, e-mail: [email protected]
^*Corresponding Author: Guillaume Bouzille, e-mail: [email protected]
^*Corresponding Author: Jean-Yves Mabrut, e-mail: [email protected]
^*Corresponding Author: Edouard Girard, e-mail: rf.elbonerg-uhc@1drarige
^*Corresponding Author: Alexis Laurent, e-mail: [email protected]
^*Corresponding Author: Francis Navarro, e-mail: rf.reilleptnom-uhc@orravan-f
^*Corresponding Author: Alexandre Chebaro, e-mail: [email protected]
^*Corresponding Author: Laurence Chiche, e-mail: [email protected]
^*Corresponding Author: Francois Faitot, e-mail: [email protected]
^*Corresponding Author: Laurent Sulpice, e-mail: [email protected]
^*Corresponding Author: Eric Vibert, e-mail: [email protected]
^*Corresponding Author: Karim Boudjema, e-mail: [email protected]

^AStudy design/planning
^BData collection/entry
^CData analysis/statistics
^DData interpretation
^EPreparation of manuscript
^FLiterature analysis/search

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 3 Patient, graft and perioperative characteristics.

	HTn=64n (%) ormedian [IQR]	CPAn=13n (%) ormedian [IQR]	RPAn=51n (%) ormedian [IQR]	P-value
Complications (Clavien-Dindo)				0.590
	27 (48)	4 (36)	23 (51)
≥IIIb	29 (52)	7 (64)	22 (49)
Anastomotic complications

Thrombosis	9 (14.1)	2 (15.4)	7 (13.7)	1.000
Stenosis	4 (6.2)	0 (0.0)	4 (7.8)	0.574

Thrombosis	10 (15.6)	5 (38.5)	5 (9.8)	0.023
Stenosis	3 (4.7)	0 (0.0)	3 (5.9)	1.000

Thrombosis	2 (3.1)	1 (7.7)	1 (2.0)	0.368
Stenosis	0 (0)	0 (0)	0 (0)	0.000

Bilioma	2 (3.1)	1 (7.7)	1 (2.0)	0.368
Biliary fistula	2 (3.1)	0 (0.0)	2 (3.9)	1.000
Graft dysfunction
PNF	7 (10.9)	3 (23.1)	4 (7.8)	0.283
Delayed function	1 (1.6)	0 (0.0)	1 (2.0)	1.000
PHT-related complications
Ascites	18 (28.1)	7 (53.8)	11 (21.6)	0.049
Hemorrhage	11 (17.2)	3 (23.1)	8 (15.7)	0.827
Encephalopathy	1 (1.6)	0 (0.0)	1 (2.0)	1.000
Renal complications
Functional ARF	22 (34.9)	5 (38.5)	17 (34.0)	1.000
Organic ARF	10 (15.6)	2 (15.4)	8 (15.7)	1.000
Postop. dialysis	6 (9.4)	1 (7.7)	5 (9.8)	1.000
Reoperation	26 (40.6)	5 (38.5)	21 (41.2)	1.000
Retransplantation	3 (4.8)	0 (0.0)	3 (5.9)	0.914
Hospital stay (days)	29.5 [19.75–43]	38 [27.25–65.25]	29 [19–37.5]	0.153
Rehospitalization	17 (28.8)	4 (36.4)	13 (27.1)	0.807
HT – hemitranspositions; CPA – cavoportal hemitransposition; RPA – renoportal hemitransposition; IQR – interquartile range; PNF – primary nonfunction; PHT – portal hypertension; ARF – acute renal failure.

Back to the Article

The Role of Cavoportal and Renoportal Hemitransposition in Liver Transplantation

Your Privacy